Clarivate Expands Agentic AI in Cortellis
Analysis based on 10 articles · First reported Aug 06, 2026 · Last updated Aug 06, 2026
The announcement is expected to strengthen Clarivate's competitive position in the life sciences intelligence market, potentially boosting demand for its Cortellis solutions. This could positively impact Clarivate's revenue growth and stock performance, while also benefiting life sciences companies by accelerating their drug development timelines.
Clarivate Plc announced the expansion of agentic AI capabilities across its Cortellis portfolio to accelerate drug development for life sciences organizations. The enhancements include natural language processing in Cortellis Drug Discovery Intelligence, multi-agent intelligence in OFF-X for proactive safety assessment, and agentic workflows in Cortellis Competitive Intelligence for faster competitive and portfolio strategy. These capabilities aim to reduce manual effort and enable faster, more informed decisions across the R&D lifecycle. Anne Lecocq, Senior Vice President and General Manager, R&D, Life Sciences & Healthcare, highlighted the evolution of Cortellis from an information source to a connected ecosystem of agentic capabilities.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard